Awarded Contractocds-b5fd17-70b4c5bd-ae37-49bf-9dfc-6fbadf695fd8

Services to deliver Onasemnogene abeparvovec/Zolgensma

Spinal muscular atrophy, or SMA, is a rare genetic disorder that causes muscle weakness and progressive loss of movement. It is most commonly caused by defects in the gene SMN1. Onasemnogene abeparvovec (Zolgensma, AveXis) is a single-use gene replacement therapy made of a viral vector that has been modified to contain the primary gene for the human survival motor neuron (SMN) protein, which is lacking or mutated in people with SMA. When injected, the vector is expected to carry the gene into the nerve cells, enabl...

Buyer

NHS Arden and Greater East Midlands Commissioning Support Unit

Value

£6,000,000

Published

30 Jun 2021

Closes

8 Mar 2021

Procurement details

Source

Contracts Finder

Region

United Kingdom

Procurement method

Open

Category

Services

Contract starts

30 May 2021

Contract ends

30 May 2026

CPV classifications

85000000

Health and social work services

Lots

Lot default Services to deliver Onasemnogene abeparvovec/Zolgensma

£6,000,000

Spinal muscular atrophy, or SMA, is a rare genetic disorder that causes muscle weakness and progressive loss of movement. It is most commonly caused by defects in the gene SMN1. Onasemnogene abeparvovec (Zolgensma, AveXis) is a single-use gene replacement therapy made of a viral vector that has been modified to contain the primary gene for the human survival...

Delivery: British Oversea Territories, Channel Islands, Europe, Isle of Man, Rest of the World, United Kingdom

Awarded contract notice on Contracts Finder

30 Jun 2021

Awarded contract notice on Contracts Finder

Award notice · Web page

Additional data

Not provided

Additional data

Link

User / Company

Not provided

User / Company

Link

Contains public sector information licensed under the Open Government Licence v3.0.